SAGE is currently trading at $24.93, up 3.96 percent or $0.95 on the Nasdaq. BIIB is currently trading at $147.98 up 1.21 percent or $1.78 on the Nasdaq. The views and opinions expressed herein ...

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi. Post the FDA approval ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Financial giants have made a conspicuous bearish move on Biogen. Our analysis of options history for Biogen (NASDAQ:BIIB) revealed 8 unusual trades. Delving into the details, we found 37% of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment. Eisai Co., Ltd. and Biogen Inc. announced that the U.S. FDA ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

$700,000 of BIOGEN lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Discussions regarding drug pricing and supply ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases.

BIIB closed Friday's regular trading at $146.20 up $2.53 or 1.76%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...